Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells

Histone deacetylase inhibitors (HDACi) are promising anti-cancer agents, and combining a HDACi with other agents is an attractive therapeutic strategy in solid tumors. We report here that mevastatin increases HDACi LBH589-induced cell death in triple-negative breast cancer (TNBC) cells. Combination treatment inhibited autophagic flux by preventing Vps34/Beclin 1 complex formation and downregulating prenylated Rab7, an active form of the small GTPase necessary for autophagosome-lysosome fusion. This means that co-treatment with mevastatin and LBH589 activated LKB1/AMPK signaling and subsequently inhibited mTOR. Co-treatment also led to cell cycle arrest in G2/M phase and induced corresponding expression changes of proteins regulating the cell cycle. Co-treatment also increased apoptosis both in vitro and in vivo, and reduced tumor volumes in xenografted mice. Our results indicate that disruption of autophagosome-lysosome fusion likely underlies mevastatin-LBH589 synergistic anticancer effects. This study confirms the synergistic efficacy of, and demonstrates a potential therapeutic role for mevastatin plus LBH589 in targeting aggressive TNBC, and presents a novel therapeutic strategy for further clinical study. Further screening for novel autophagy modulators could be an efficient approach to enhance HDACi-induced cell death in solid tumors.


INTRODUCTION
Breast cancer is the second leading cause of cancerrelated deaths among women in the United States, with over 246,660 new diagnoses expected in 2016 and approximately 40,450 deaths [1].Current clinical therapies include hormone-based agents that directly target estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2) [2,3].Triplenegative breast cancer (TNBC) is ER-, PR-and HER2negative, and accounts for approximately 15% of all breast cancers [3][4][5].TNBC is an aggressive subtype that does not respond to ER-, PR-, or HER2-targeted therapies, and TNBC patient prognoses are poor [3,6].
LBH589 is an HDACi shown to suppress TNBC cell growth at nanomolar concentrations [15,16].LBH589 treatment reduced tumor load in vivo and increased overall Research Paper www.impactjournals.com/oncotargetsurvival in treated mice [13,17].LBH589 combined with other agents may improve treatment efficacy and provide an attractive therapeutic strategy for TNBC.In this study, we show that the combination of mevastatin [18] and LBH589 inhibits TNBC cell proliferation by downregulating the cell cycle regulator, cyclin D1, upregulating P21 activity, and enhancing apoptosis.We show that mevastatin increases autophagososme formation, but decreases autolysosome maturation, potentiating LBH589-induced TNBC cell death.Our results also demonstrate that cellular stress induced by mevastatin plus LBH589 activates LKB1/AMPK to promote TNBC cell death.This activation inhibited mTOR, p70S6K, and cyclin D1, and induced apoptosis.In addition, treatment reduced Rab7 prenylation, inhibiting autolysosome maturation.Mevastatin plus LBH589 also decreased tumor volume in an in vivo TNBC xenograft tumor model.Thus, our results show that mevastatin plus LBH589 is a potentially efficacious therapeutic strategy for treating TNBC.
Anti-proliferation activity was further analyzed by annexin-V and PI staining, followed by flow cytometry to measure apoptosis.Mevastatin or LBH589 caused slight increases in apoptotic MDA-MB-231 and MDA-MB-468 cells compared with controls.Combination treatments increased apoptotic and necrotic cells compared to either mevastatin or LBH589 alone in a mevastatin dosedependent manner.Annexin-V positive MDA-MB-231 and MDA-MB-468 cells increased from 11% and 12% to 69% and 40%, respectively, after 24 h treatment.These results show that combination treatments dramatically induced MDA-MB-231 and MDA-MB-468 cell death (Figure 1D-1E).To assess caspase involvement in combination treatment-induced cell death, cleavage of PARP, and caspase 8, 3, and 9 was examined.Dosedependent increased cleavage of caspase 8, 3, and 9, and PARP was observed after 24 h of combined treatment, compared to single agents (Figure 1F-1G).

Mevastatin enhances LBH589-induced G 2 -M phase arrest in human TNBC cells
Statins inhibit cancer cell proliferation by arresting the cell cycle at G 1 -S phase and inducing apoptosis via both mevalonate-dependent pathway and -independent pathways [26].We performed cell cycle analyses via flow cytometry.Mevastatin treatment in MDA-MB-231 cells increased the percentage of cells in G 1 -G 0 phase from 58% to 81% after 24 h in a dose-dependent manner, and decreased cells in S phase.Treatment with LBH589 (25 nmol/L) for 24 h decreased the percentage of S phase cells from 36% to 16%, and increased cells in G 1 -G 0 and G 2 -M phases.Combination treatment in MDA-MB-231 cells increased G 2 -M phase arrest from 5% to 55% after 24 h www.impactjournals.com/oncotarget in a mevastatin dose-dependent manner, and decreased cells in S and G 1 -G 0 phases (Figure 2A).A similar cell cycle distribution was observed in MDA-MB-468 cells (Figure 2B): 24-hour treatment with both mevastatin and LBH589 enhanced G2-M phase arrest (from 12% to 43%) and reduced cells in S and G 1 -G 0 phases.Cell cycle proteins were analyzed by Western blotting.24 h combination treatments in MDA-MB-231 and MDA-MB-468 cells downregulated cyclin D1 and survivin, and upregulated p21 in a mevastatin dose-dependent manner (Figure 2C-2D).

Mevastatin plus LBH589 activates the LKB1-AMPK energy-sensing pathway
We evaluated the effects of combination treatment on intracellular AMPK, AKT, and p42/p44 MAPK (ERK1/2) signaling activation in MDA-MB-231 and MDA-MB-468 cells.24-h mevastatin and LBH589 treatment increased AMPKα phosphorylation at Thr-172, compared to mevastatin alone, in a dose-dependent manner (Figure 4A-4B).AMPK activation is associated with decreased mTOR and p70S6K activation [27].Combined treatment decreased mTOR activation, as shown by dosedependent decreased mTOR expression and reduced phosphorylated p70S6K, compared to single agents and controls (Figure 4A-4B).LKB1 is a tumor suppressor that phosphorylates AMPK at Thr-172 [28].Its activation was investigated by measuring AMPK phosphorylation at Thr-172 and LKB1 Ser-428 phosphorylation.Combination treatment decreased phosphorylation of AKT and ERK, but not MEK, indicating that the combination effect did not activate Ras/Raf signaling (Figure 4C-4D).

Mevalonate pathway inhibition and LKB1/ AMPK activation are involved in mevastatin and LBH589-dependent TNBC cell death
Mevastatin specifically inhibits the rate-limiting enzyme, HMGCR, in the mevalonate pathway.We found that combination treatment-induced cell proliferation inhibition was reversed by addition of mevalonate.250 μM of mevalonate (MVA) impaired mevastatin (MEV) antiproliferation activity in both MDA-MB-231 and MDA-MB-468 cells, and recovered cell viability from 73% and 65% to 94% and 91%, respectively (Figure 5A-5B).Moreover, the mevastatin plus LBH589 synergistic effect was abolished by mevalonate addition (Figure . 5A-5B).Cell viability increased from 14% and 7.8% to 45% and 52%, respectively, in high mevastatin dose (2 µM and 16 µM)-treated MDA-MB-231 and MDA-MB-468 cells.However, mevalonate did not reverse the effect of LBH589 on cell growth in either cell line, indicating that the mevalonate pathway does not participate in LBH589induced cell death.
In addition to the mevalonate pathway, our results suggested that combination treatment synergy requires AMPK and mTOR signaling.Compound C (C in Figures) is an AMPK inhibitor that blocks AMPK metabolic and anti-apoptotic activities [29].TNBC cells  Western blotting confirmed that combination treatment induced apoptosis through mevalonate pathway blockage and LKB1/AMPK activation.Combined treatment increased AMPKα phosphorylation at Thr-172 compared to single agents and controls (Figure 4A-4B and 5E-5F).Increased AMPK activation inactivated mTOR, as evidenced by diminished mTOR, p-p70S6K, and cyclin D1 levels in both MDA-MB-231 and MDA-MB-468 cells.Combination treatment-induced AMPK, p70S6K, and LKB1 phosphorylation was abolished by 250 μM of mevalonate.p70S6K phosphorylation was subsequently restored by 2 μM of compound C, which decreased AMPK, but not LKB1, phosphorylation.We also tested whether combination treatment-induced apoptosis could be rescued through the AMPK and mevalonate pathways.Indeed, apoptosis-related protein cleavage was reduced by mevalonate or compound C (Figure 5G-5H).This suggests that both AMPK and mevalonate signaling participate in combination treatment-induced TNBC cell apoptosis.
We performed qPCR to determine whether mevastatin or combination treatment-induced p62/SQSTM1 downregulation was due to transcriptional inhibition.Mevastatin suppressed p62/SQSTM1 expression, and this was more pronounced with co-treatment (Figure 6C).Thus, mevastatin inhibits p62/SQSTM1 transcription, but not through autophagy induction.
Combination treatments showed pronounced dosedependent Vps34 and Beclin1 reduction observed after 24 h, compared with single agents in MDA-MB-231 cells (Figure 6D).Mevastatin abolished LBH589-induced Beclin1-Vps34 complex formation (Figure 6E).These results, together with mevastatin-induced NBR1 accumulation, suggest that mevastatin may not only block Beclin1-Vps34 complex assembly to reduce the autophagosome formation, but also may impair autophagosome-lysosome fusion for adaptor protein degradation.
To address whether mevastatin disrupted autophagosome-lysosome fusion, we analyzed co-treated MDA-MB-231 cells stably expressing RFP-GFP-LC3 (tfLC3).tfLC3 contains microtubule-associated protein 1 LC3 fused with a pH-sensitive tandem fluorescent fusion protein consisting of monomeric red fluorescent protein (mRFP) and enhanced green fluorescent protein (eGFP).GFP, but not mRFP, signals are quenched in acidic environments after autophagosome-lysosome fusion.In initial autophagic vacuoles, tfLC3 emits green and red fluorescence (merged as yellow), whereas in autophagic vacuoles, only red fluorescence is observed.We investigated the effects of the combined treatment on autophagy maturation by comparing colocalized puncta (yellow dots) and mRFP puncta (red dots).Consistent with previous reports [31,32], LBH589 increased autophagic flux, shown by decreased GFP puncta and increased RFP puncta (Figure 6F).Notably, mevastatin-or LBH589-treated cells differed: both exhibited green and red puncta, but LBH589 treatment produced fewer yellow puncta, indicating that mevastatin induced autophagosome, but not autolysosome maturation.Co-treatment produced more yellow puncta, indicating that combination treatment might block autophagosome-lysosome fusion to inhibit autophagic flux.
Rab7 is a small GTPase critical in autophagosome/ endosome maturation [33,34], and its activation requires prenylation.To confirm that mevastatin interrupts autophagosome-lysosome fusion mainly via Rab7, cell death was analyzed in Rab7 overexpressing MDA-MB-231 cells treated with LBH589 plus mevastatin.Rab7 overexpressing   cells exhibited resistance to combination treatment (Figure 6G).Inefficient fusion with endosomes and/or lysosomes would inhibit autophagosome maturation to amphisomes or autolysosomes, thus inhibiting autophagy.Mevastatin treatment blocked mevalonate signaling, dose-dependently decreasing prenylated Rab7 (Figure 6H).Combination treatment further decreased Rab7 prenylation in comparison to single agents, suggesting that co-treatment enhanced autophagy blockade.Consistent with confocal microscopy observations, our results indicated that combination treatment blocked autophagosome-lysosome fusion.

DISCUSSION
HDAC dysregulation in cancer cells leads to gene expression changes and regulates cancer cell viability [12,35].Drugs that inhibit HDAC in cancer cells increased survival in mice bearing TNBC cell xenografts [16,31].However, HDACi exhibit only limited effectiveness in low concentrations in solid tumors [7,12].A potential solution to this limitation is combination therapy.LBH589 has been evaluated in clinical trials in combination with other drugs [8,11,15].Our study employed an unbiased combinatorial screening, including over 1000 drug combinations, to assess synergistic effects of LBH589 with other drugs for TNBC therapeutic application.We found that treatment with LBH589 and mevastatin synergistically reduced MDA-MB-231 and MDA-MB-468 cell proliferation and increased apoptosis (Supplementary Figure 1).Co-treatment decreased tumor growth in in vivo MDA-MB-231 xenografts with minimal toxicity.
Statins reportedly exert anti-tumor and antiproliferation activities in vitro and in vivo, and the clinical utility of these drugs continues to evolve [36].Statins may exert anti-cancer effects through decreased mevalonate synthesis, and downregulation of products downstream of mevalonate, including dolichol, geranylpyrophosphate and farnesylpyrophosphate.Recent studies indicate important roles for statins in autophagy: autophagy induction through decreased GGPP, and autophagy blockade through decreased prenylated RhoA [22,[37][38][39][40][41].
We investigated the effects of mevastatin alone or in combination with LBH589 on the initial stage of autophagy, autophagic vesicle formation, and the late stage, autolysosome formation.We employed RFP-GFP-LC3 (tfLC3) fluorescent analysis to investigate the hypothesis that autophagy blockade is involved in the cellular response to co-treatment.A ratio of yellow/RFPpositive puncta = 1 indicated autophagy blockage, while a ratio < 1 indicated abnormally reduced autophagosomelysosome fusion.The decreased yellow/RFP-positive puncta ratio in LBH589-treated cells confirmed autophagy induction and increased autolysosome formation as previously reported [25].Our results also demonstrated that mevastatin induced autophagy, but this was partially impaired by reduced autophagosome-lysosome fusion, as  Rab7 is one of the most important effectors in autophagolysosome maturation, promoting microtubule plus-end-directed transport, and facilitating autophagosome-lysosome fusion [34].Our results showed that mevastatin or mevastatin-LBH589 cotreatment decreased autophagosome-lysosome fusion through downregulation of prenylated Rab7.This could be reversed by mevalonate addition, or partially rescued by the AMPK inhibitor, compound C, indicating that the mevalonate pathway is involved in autophagosomelysosome fusion through Rab7 prenylation.Other studies also suggest that lysosomal positioning proteins, such as TFEB (transcription factor EB) and the AAA-type ATPase SKD1, also impair autophagosome-lysosome fusion [42,43].Thus, other factors may contribute to the co-treatment autophagosome-lysosome fusion inhibitory effect.Vps34 forms a complex with Beclin 1 in phosphoinositide generation, which is essential for autophagic vesicle formation.Our co-IP results revealed Vps34/Beclin 1 complex formation disruption in mevastatin plus LBH589-treated cells.This blockade inhibits autophagy initiation by reducing autophagosome formation, contributing to disruption of autophagy flux.
In summary, autophagy blockade was examined as a potential mechanism underlying the synergistic enhancement of anticancer activity via mevastatin-LBH589 combination treatment (Figure 8).We investigated the effects of mevastatin on autophagy and apoptosis.We showed that mevastatin inhibits autophagic flux by abrogating autophagosome-lysosome fusion, and this activity is enhanced by LBH589.Notably, we demonstrated that mevastatin stimulates LBH589-induced apoptosis in TNBC cells.The combination effect was observed both in vitro and in vivo in a xenograft model.Our results confirm the synergistic efficacy of, and demonstrate a potential therapeutic role for mevastatin plus LBH589 in targeting aggressive TNBC, and offer a new therapeutic strategy for further clinical study.Further screening for novel autophagy modulators could be an efficient approach to enhance HDACi-induced cell death in solid tumors.

Screening of hits in combination with LBH589
MDA-MB-231 cells was seeded in 384 well plates at a density of 12,000 cells per well.Cellular proliferation assay (CCK8 assay) was used for measurement of the cytotoxic effect.An integrated Agilent Biocel 900 System containing direct drive robot (DDR), Liconic CO 2 incubator, Thermo combi dispenser, liquid handler (Bravo), and a multipurpose reader (Envision, PerkinElmer) enabled high-throughput readout of cell survival after compounds treatment.The substances used in combination with LBH589 were 1,280 pharmacologically active compounds from sigma (LOPAC ® 1280).Cells treated with compounds (10 µM) and/or LBH589 (25 nM) for 48 h followed by cell proliferation detection.

Cell cycle analysis
MDA-MB-231 and MDA-MB-468 cells were seeded in a 6-well plate at 5.0 × 10 5 cells/well and treated with mevastatin and LBH589.24 h later, cells were harvested with trypsin and fixed with EtOH at 4°C for 3 h.Cells were then centrifuged at 1,500 g for 5 min and washed with PBS.Cells were resuspended in RNase/PBS solution (20 µg/ml), incubated at 37°C for 15 min, added to propidium iodide (PI)/PBS solution (20 µg/ml), and incubated at RT for 30 min.Stained cells were analyzed via a FACSCalibur (Becton Dickinson, New Jersey, USA) and data were analyzed using CellQuest Pro software (Becton Dickinson).

Apoptosis analysis
MDA-MB-231 and MDA-MB-468 cells were seeded in a 6-well plate at 5.0x10 5 cells/well and treated with mevastatin and LBH589.24 h later, cells were harvested with trypsin and washed once with pre-cooled PBS.Cells were re-suspended in 500 µl 1× binding buffer, and 5 µL PI and 5 μl annexin-V (Becton Dickinson) were added.After incubation in the dark (room temperature) for 10 min, stained cells were analyzed via a FACSCalibur instrument and CellQuest Pro software.

Determination of combination effect
MDA-MB-231 and MDA-MB-468 cells were plated in 96-well microplates at 2×10 4 cells/well.Cells were treated for 48 h with mevastatin from 30 to 0.47 µM with 2-fold dilutions, LBH-589 from 150 to 2.3 nM with 2-fold dilutions, or their corresponding combinations.Synergism after drug treatments was quantitated using the combination index (CI) method in ED50, ED75 and ED90 by Calcusyn software.The Chou and Talalay method was used to calculate combination index (CI).CI > 1, = 1, or < 1 indicates antagonism, additive effect, or synergy, respectively.Each CI ratio is the mean value derived from at least three independent experiments.

Separation of prenylated and unprenylated proteins
Triton X-114 fractionation was used to separate prenylated and unprenylated Rab7 in whole cell lysates from cultures treated with mevastatin and LBH589.Triton X-114 enables separation of hydrophilic proteins from amphiphilic proteins; therefore, lipophilic, prenylated Rab7 partitions into the detergent-rich phase, whereas unprenylated Rab7 remains in the aqueous phase.www.impactjournals.com/oncotargetMDA-MB-231 cells were harvested following mevastatin and LBH589 treatment by scraping into medium and pelleting via centrifugation at 1500×g.Cell pellets were washed once in PBS before being lysed in Triton X-114 buffer (20 mM Tris, 150 mM NaCl, pH 7.5, 1% Triton X-114, protease inhibitor cocktail) for 15-20 min at 4°C.Lysates were cleared by centrifugation at 13,000 × g for 15 min at 4°C, and then incubated at 37°C for 10 min.Following centrifugation at 13,000×g for 2 min at room temperature, the top aqueous clear layer was transferred to a new microfuge tube.Buffer without Triton X-114 (20 mM Tris, 150 mM NaCl, pH 7.5, protease inhibitor cocktail) was added to the bottom detergent-rich layer to equalize the volume with the aqueous phase, and protein was electrophoresed on 12% polyacrylamide gels.Gels were analyzed by Western blotting for Rab7 and GAPDH.

Quantitative real-time PCR (qPCR) analysis
MDA-MB-231 cells were harvested following mevastatin and LBH589 treatment.RNA was isolated with RNeasy Plus Mini kits (QIAGEN) according to the supplier's protocol.Total RNAs (500 ng) was reversetranscribed in 25 µl using TaqMan ® Reverse Transcription Reagents (Applied Biosystems, Inc.).
Each qPCR reaction was performed with 2.5 μL cDNA in 20 µl total volume using the SYBR® Green PCR Master Mix.Reaction conditions were as follows: initial denaturation at 95°C for 10 min followed by 40 cycles at 95°C for 10 s, 60°C for 10 s and extension at 72°C for 15 s, then 10 min at 72°C, and 55°C rise to 95°C for melt curves.Primers used included: p62/SQSTM1 (5›-GCA CCC CAA TGT GAT CTG C-3›, 5›-CGC TAC ACA AGT CGT AGT CTG G-3›) and GAPDH (5›-GGA GCG AGA TCC CTC CAA AAT-3›, 5›-GGC TGT TGT CAT ACT TCT CAT GG-3›).All samples were analyzed in triplicate, and reactions were performed using a LightCycler 480 II PCR machine (Roche Diagnostic, Inc.).PCR product amounts were normalized first to GAPDH, and then to levels in control cells as 1.

In vivo drug activity
MDA-MB-231 (1×10 7 cells in 0.2 ml PBS) were injected into the left armpits of 5-6-week old BALB/c nu/nu athymic female mice (Sino-British SIPPR/BK Lab.Animal Ltd, China).Tumor volume (mm 3 ) was measured with calipers and calculated as (W2×L)/2, where W is width and L is length.When tumor volume reached ~100 mm 3 , mice were randomized into four groups (five mice per group) including control, mevasatin (10 mg/kg orally daily), LBH589 (0.5 mg/kg intraperitoneal injection (ip) daily) and mevastatin (10 mg/kg orally daily) plus LBH589 (0.5 mg/kg ip daily) groups, and treatments were initialized.Sterilized drinking water containing PBS was supplied to control mice.Tumor volumes were recorded every five days.Animals were sacrificed 35 days postinduction.Tumor tissues were collected and subjected to Western blotting analyses for relative protein expression, and TUNEL assay.

TUNEL assay
TUNEL (terminal deoxynucleotidyltransferasemediated dUTP nick end labeling) assay was carried out using "In situ cell death detection kit, fluorescein" (Roche, USA) according to the manufacturer's instructions.Slides were rinsed twice with PBS.After drying areas around the sample, 50 µl TUNEL reaction mixture was added.After rinsing three times with PBS, samples with fluorescein labels incorporated in nucleotide polymers were detected by fluorescence microscopy.Nuclei were counted by counter staining with 4,6-diamidino-2-phenylindole (DAPI) at excitation wavelength, 350 nm.

Statistical analysis
All results were expressed as means ± SD of three independent experiments.Statistical analyses were performed using Student's two-tailed t-test by Graphpad Prism 6.07 software.P < 0.05 was considered significant.

Figure 4 :
Figure 4: Mevastatin and LBH589 activate AMPK and inhibit mTOR in TNBC cell lines.AMPK involvement in the synergistic effects of mevastatin and LBH589 on MDA-MB-231 (A) and MDA-MB-468 (B) cells for 24 h.Cell lysates were immunoblotted with indicated antibodies.Co-treatment effect on ERK does not depend on Ras in MDA-MB-231 (C) and MDA-MB-468 (D) cells after 24 h.Cell lysates were analyzed by Western blotting for phosphorylated or total MEK, phosphorylated or total ERK, with GAPDH as an internal control.MDA-MB-231 (E) and MDA-MB-468 cells (F) were treated with mevastatin plus LBH589 for 6, 12, 24 and 36 h.Lysates were immunoblotted with the indicated antibodies.

Figure 5 :
Figure 5: The mevalonate pathway is involved in mevastatin enhancement of LBH-induced TNBC cell death.Mevalonate and compound C rescued mevastatin-induced proliferation inhibition in MDA-MB-231 and MDA-MB-468 cells.Prior to mevastatin and/ or LBH589 (25 nM) treatment for 48 h, MDA-MB-231 (A) and MDA-MB-468 (B) cells were incubated with or without mevalonate (250 μM) for 6 h.Alternatively, prior to treatment, MDA-MB-231 (C) and MDA-MB-468 (D) cells were incubated with or without compound C (1, 2 μM) for 2 h.Mevalonate and compound C blocked LKB1/AMPK signaling in MDA-MB-231 (E) and MDA-MB-468 (F) cells treated with indicated agents for 24 h.Cell lysates were immunoblotted with indicated antibodies.Mevalonate and Compound C reduced cleavage of apoptosis-related proteins in MDA-MB-231 (G) and MDA-MB-468 (H) cells.Cleavage of PARP, and caspases 8 and 3 was analyzed by Western blotting.Data are representative of at least three experiments.Student's t-test.**P < 0.01; ***P < 0.001.

Figure 7 :
Figure 7: Mevastatin plus LBH589 enhances TNBC cell death in vivo in MDA-MB-231 cell xenografted mice.Photographs of subcutaneous tumors resulting from indicated treatments in xenografted nude mice (A).Tumor-bearing mice were treated with vehicle control, mevastatin (10 mg/kg orally daily), LBH589 (0.5 mg/kg intraperitoneal injection daily), or combination as indicated (B).Mouse body weight curves following treatments (C).Detection of DNA strand breaks by TUNEL assay in MDA-MB-231 tumors after treatment with vehicle, mevastatin (10 mg/Kg orally daily), LBH589 (0.5 mg/kg intraperitoneal injection daily), or combination (D) Green fluorescence indicates TUNEL positive cells.Tumors were stained with DAPI to identify nuclei.Quantitative evaluation of TUNEL positive cells treated with indicated agents (E).Five images were analyzed in each group; bars over columns represent means ± SD; Student's t-test.**P < 0.01; ***P < 0.001.Immunoblotting analysis of xenograft tumor tissues (F and G).
indicated by yellow/RFP-positive puncta.In co-treated cells, overwhelming RFP-positive/GFP-positive puncta co-localization indicated disruption of autolysosome maturation and subsequent blockade of autophagy flux.

Figure 8 :
Figure 8: Schematic diagram of the antitumor activities of mevastatin and LBH589 in TNBC.This schematic diagram shows that mevastatin increased HDACi LBH589-induced cell death in TNBC cells.Combination treatment inhibited autophagic flux by preventing Vps34/Beclin 1 complex formation and the maturation of autophagosome-lysosome via down regulated prenylated Rab7 as well as the activity of P70S6K by activated LKB1/AMPK signaling, resulting in Caspase8 dependent cell death.